Knowledge accumulation and industry evolution : the case of Pharma-Biotech

Frontmatter......Page 1
Contents......Page 7
List of figures......Page 9
List of tables......Page 12
List of contributors......Page 14
Acknowledgments......Page 17
1 - Introduction......Page 19
Part I - Innovation and industry evolution......Page 37
2 - Pharmaceutical innovation as a process of creative destruction......Page 39
3 - The evolution of pharmaceutical innovation......Page 90
4 - Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals......Page 129
5 - Innovation and industry evolution: a comment......Page 162
Part II - Firm growth and market structure......Page 178
6 - Heterogeneity and firm growth in the pharmaceutical industry......Page 180
7 - Growth and diversification patterns of the worldwide pharmaceutical industry......Page 224
8 - Entry, market structure, and innovation in a â•œhistory-friendlyâ•š model of the evolution of the pharmaceutical industry......Page 250
9 - The growth of pharmaceutical firms: a comment......Page 282
Part III - Policy implications......Page 291
10 - The effects of research tool patents and licensing on biomedical innovation......Page 293
11 - Upstream patents and public health: the case of genetic testing for breast cancer......Page 343
12 - Competition, regulation, and intellectual property management in genetically modified foods: evidence from survey data......Page 362
13 - Governance, policy, and industry strategies: pharmaceuticals and agro-biotechnology......Page 394
14 - The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector: policy issues......Page 418
Index......Page 448